Biotie Therapies - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Biotie Therapies Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Biotie Therapies. The Group's principal activity is the research and development of drugs for dependence disorders, inflammatory diseases, glycomics applications and thrombosis. The Group's products focus on widespread diseases such as alcohol dependency, rheumatoid arthritis, inflammatory bowel disease, psoriasis, thrombosis and cancer. The Group's 'nalmefene' is the first tablet form drug demonstrating efficacy in reducing heavy drinking in multicenter. Other products include VAP-1 monoclonal which I s an antibody for inflammatory diseases, VAP-1 SSAO is enzyme inhibitor for inflammatory diseases and Integrin 2 B1 is inhibitor for thrombosis.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report